Profound Medical (PROF) Other financing activities (2024)
Profound Medical's (PROF) quarterly Other financing activities came in at $4.9 million in Q4 2024, up 363.4% quarter-over-quarter from -$1.9 million in Q2 2024.
Profound Medical (PROF) Other financing activities (2024) Analysis & Trends
Profound Medical's Other financing activities history runs 1 years deep, the most recent figure standing at $4.9 million for Q4 2024.
- On a quarterly basis, Other financing activities changed N/A year-over-year to $4.9 million in Q4 2024; TTM through Dec 2024 was $4.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $8000.0, down 99.84% from the prior year.
- Other financing activities climbed to $4.9 million in Q4 2024 per PROF's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Other financing activities topped out at $4.9 million in Q4 2024 and bottomed at -$1.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Profound Medical | 248.64 Mn | 198.34 Mn | 3.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.89 Mn |
| Dec 31, 2024 | 4.89 Mn |
| Jun 30, 2024 | -1.86 Mn |
| Jun 30, 2024 | -1.86 Mn |
| Mar 31, 2024 | 1.86 Mn |
| Mar 31, 2024 | 1.86 Mn |